Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator ...

Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool has positions in and ...

Axsome Therapeutics, Inc. remains a Sell due to an undifferentiated CNS pipeline, heavy SG&A and net losses. Learn more about ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the ...

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growthAUVELITY® 3Q 2025 net product sales of $136.1 million, ...

Q3 2025 Earnings Call Transcript November 3, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue ...

Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...

About Avenue Therapeutics Avenue Therapeutics, Inc. (OTC: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic ...

Axsome Therapeutics AXSM is preparing to release its quarterly earnings on Monday, 2025-08-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ...